Newsletter - Alzheimer Europe May 2022 newsletter https://alzheimereurope.newsweaver.com/Newsletter/ en-us 01 Jun 2022 03:17:13 CEST 01 Jun 2022 03:17:13 CEST https://alzheimereurope.newsweaver.com/Newsletter/rss.xml Newsweaver info@alzheimer-europe.org () support@newsweaver.ie (Newsweaver) 60 true Welcome https://alzheimereurope.newsweaver.com/Newsletter/hyc3buvw7g1?lang=en?rss=true Alzheimer Europe’s May 2022 newsletter [ https://alzheimereurope.newsweaver.com/Newsletter/5f0urhu8wx1/external ] [ https://alzheimereurope.newsweaver.com/Newsletter/5f0urhu8wx1/external ] brings you the latest news on developments in the dementia field, across Europe and beyond. Summaries of a few of our top stories appear below. Our monthly newsletter reaches around 12,000 people and we are always happy to receive feedback, or suggestions regarding news items to share. [ https://alzheimereurope.newsweaver.com/Newsletter/5f0urhu8wx1/external ] 01 Jun 2022 12:00:00 CEST 0c48c3b7622c4a9d6840bda496926d48 Feature Article <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/2b/92a8976269fb1f449eddd2.jpg" style="margin: 5px;" width="150" height="100" hspace="5" vspace="5" alt="" />Alzheimer Europe’s<strong> <a href="https://alzheimereurope.newsweaver.com/Newsletter/5f0urhu8wx1/external" target="_blank" rel="noreferrer noopener"><strong>May 2022 newsletter</strong></a> </strong>brings you the latest news on developments in the dementia field, across Europe and beyond.</p> <p style="text-align: justify;">Summaries of a few of our top stories appear below.</p> <p style="text-align: justify;">Our monthly newsletter reaches around 12,000 people and we are always happy to receive feedback, or suggestions regarding news items to share.</p> <p style="text-align: justify;"> </p> <p class="centered-only" style="text-align: center;"><a href="https://alzheimereurope.newsweaver.com/Newsletter/5f0urhu8wx1/external" target="_blank" rel="noreferrer noopener"><img align="middle" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/33/9a2b2c753c2ca4ee114ecc.jpg" style="margin: 0px;" width="200" height="48" hspace="0" vspace="0" alt="" /></a></p> 12 May: Alzheimer Europe co-hosts webinar on Patient involvement in Brain Health and launches call to action https://alzheimereurope.newsweaver.com/Newsletter/1b3d7ccsxo3?lang=en?rss=true Alzheimer Europe co-organised a webinar with the European Federation of Neurological Alliances (EFNA) and GAMIAN-Europe, on "Patient involvement in Brain Health: Safeguarding the future of Brain Health for patients". A joint Call to Action was also launched, highlighting the need for improved Patient Involvement in brain health research in Europe. Helen Rochford-Brennan was among the speakers, highlighting that people with dementia must be equal partners in research. 01 Jun 2022 12:00:00 CEST 093dafde2596289c6ab4e6105e53e7f6 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/34/9b5786c4ab10de46d16c2e.jpg" style="margin: 5px;" width="150" height="100" hspace="5" vspace="5" alt="" />Alzheimer Europe co-organised a webinar with the European Federation of Neurological Alliances (EFNA) and GAMIAN-Europe, on "Patient involvement in Brain Health: Safeguarding the future of Brain Health for patients". A joint Call to Action was also launched, highlighting the need for improved Patient Involvement in brain health research in Europe. Helen Rochford-Brennan was among the speakers, highlighting that people with dementia must be equal partners in research.</p> https://www.alzheimer-europe.org/news/alzheimer-europe-co-hosts-webinar-patient-involvement-brain-health-safeguarding-future-brain 13 May: EWGPWD meets face to face for the first time in over two years and re-elects Chairperson https://alzheimereurope.newsweaver.com/Newsletter/gbjxs95ltjx?lang=en?rss=true The European Working Group of People with Dementia (EWGPWD) met face-to-face this month, for the first time in over two years. They worked on several projects, within the framework of Public Involvement. At the meeting, Chris Roberts was re-elected as Chairperson, for the next term of office (starting from October). The group also discussed the organisation of its special symposium at the 32nd Alzheimer Europe Conference. 01 Jun 2022 12:00:00 CEST 7b5de7b8311c5e8ff24f0d50cd7dfdae Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/14/4ec4d85021836002c4270c.jpg" style="margin: 5px;" width="150" height="113" hspace="5" vspace="5" alt="" />The European Working Group of People with Dementia (EWGPWD) met face-to-face this month, for the first time in over two years. They worked on several projects, within the framework of Public Involvement. At the meeting, Chris Roberts was re-elected as Chairperson, for the next term of office (starting from October). The group also discussed the organisation of its special symposium at the 32nd Alzheimer Europe Conference.</p> <p style="text-align: justify;"> </p> <p style="text-align: justify;"> </p> https://www.alzheimer-europe.org/news/ewgpwd-meets-face-face-first-time-over-two-years 15 May: It has been 20 years since the last approval of an Alzheimer’s medication in Europe https://alzheimereurope.newsweaver.com/Newsletter/hu6lsung0o9?lang=en?rss=true It has been 20 years since the last approval of an Alzheimer’s medicine by the European Medicines' Agency, meaning that people living in Europe affected by Alzheimer’s disease (AD) have been waiting to gain access to better treatments for two decades. With Biogen’s recent withdrawal of its marketing authorisation application for aducanumab, the wait goes on. 01 Jun 2022 12:00:00 CEST 58e5d5cbdef4d3dd6048bd4b2f096743 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/35/d7e6034300d800d1c7e587.jpg" style="margin: 5px;" width="150" height="100" hspace="5" vspace="5" alt="" />It has been 20 years since the last approval of an Alzheimer’s medicine by the European Medicines' Agency, meaning that people living in Europe affected by Alzheimer’s disease (AD) have been waiting to gain access to better treatments for two decades. With Biogen’s recent withdrawal of its marketing authorisation application for aducanumab, the wait goes on.</p> <p style="text-align: justify;"> </p> <p style="text-align: justify;"><span style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; color: #000000;"><span style="text-align: justify; background-color: #ffffff; display: inline; float: none;"><br /></span> </span></p> https://www.alzheimer-europe.org/news/it-has-been-20-years-last-approval-alzheimers-medication-europe 15 May: Call for abstracts for the 32nd Alzheimer Europe Conference is closed https://alzheimereurope.newsweaver.com/Newsletter/f8cg3a987ch?lang=en?rss=true The call for abstracts is now closed for the 32nd Alzheimer Europe Conference, which will take place in Bucharest, Romania, under the banner “Building Bridges”. We are pleased to have received almost 270 abstracts, all of which are now being reviewed by the Scientific Committee. All submitting authors will be informed of the Committee's decision in mid-June. 01 Jun 2022 12:00:00 CEST 0332ef58ded724000e2615532c33d2d9 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/17/1dbfa1ad10bcfb0ad428a8.jpg" style="margin: 5px;" width="150" height="100" hspace="5" vspace="5" alt="" />The call for abstracts is now closed for the 32nd Alzheimer Europe Conference, which will take place in Bucharest, Romania, under the banner “Building Bridges”. We are pleased to have received almost 270 abstracts, all of which are now being reviewed by the Scientific Committee. All submitting authors will be informed of the Committee's decision in mid-June. </p> <p style="text-align: justify;"> </p> <p style="text-align: justify;"> </p> https://www.alzheimer-europe.org/news/call-abstracts-32nd-alzheimer-europe-conference-closed 27 May: World Health Assembly passes neurological conditions action plan https://alzheimereurope.newsweaver.com/Newsletter/1a52yr0jg02?lang=en?rss=true Delegates at the 75th World Health Assembly have approved a new intersectoral global action plan on epilepsy and other neurological disorders (including stroke, migraine, dementia and meningitis) that aims to improve access to care and treatment for people living with these conditions, while preventing new cases and promoting brain health and development across the life course. 01 Jun 2022 12:00:00 CEST 360931fe248ea21ee09b4f2bfcad0463 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/ab/e166caa8b1a3ed58941747.jpg" style="margin: 5px;" width="150" height="100" hspace="5" vspace="5" alt="" />Delegates at the 75th World Health Assembly have approved a new intersectoral global action plan on epilepsy and other neurological disorders (including stroke, migraine, dementia and meningitis) that aims to improve access to care and treatment for people living with these conditions, while preventing new cases and promoting brain health and development across the life course.</p> <p style="text-align: justify;"> </p> https://www.alzheimer-europe.org/news/world-health-assembly-passes-neurological-conditions-action-plan